MBX Biosciences (MBX) Appoints Steve Hoerter to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St ends higher on cool inflation data, strong earnings
- U.S. headline producer inflation posts first one-month decrease since August 2025
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices make small gain on smaller US inventory draw
- ASML capacity upgrade soothes AI chip bottleneck fears
MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors
April 7, 2025 8:00 AM EDTCARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Steve Hoerter as an independent director to the Companys Board of Directors. Mr. Hoerter brings over three decades of pharmaceutical commercialization and executive leadership experience as well as a proven track record of building and growing life science companies.
I am thrilled to welcome Steve Hoerter to the Companys Board as an... More
